Reaxys is a platform-independent, web-based product, so it doesn't require any installation. If you wish to operate in a Java-free environment, you should ensure that either GGA Ketcher or Elemental are your default editors. If you wish to run any other structure editor, Java version 1.5 or higher is a prerequisite.
Customers can access the product at www.reaxys.com. Platform independency means that it runs on Windows and Apple operating systems. We support Internet Explorer (6 or higher), Firefox (3 or higher) and Safari (4 or higher). Technical requirements are available in the Technical Product Info section.
Please Contact Sales to set up a demonstration.
We offer Corporate/Campus-Wide Access licenses at a flat-rate on a yearly subscription basis. This includes user authentication via IP-recognition so no individual user credentials are needed. This also means there are no seat-based delays or budgetary concerns about task-based searches.
Since Reaxys is web-based, remote access from outside your institution is also possible.
Reaxys currently supports Shibboleth but not ATHENS.
Yes. The full-text links in Reaxys gives direct access to the publisher home pages, including ScienceDirect, EspaceNet (the European Patent Office), and USPTO (the US Patent Office). Access to ScienceDirect and external publisher content requires a subscription license. EspaceNet and USPTO are publicly available.
Yes. Reaxys provides links to and from Scopus for all matching articles.
Elsevier has matched the compounds in Reaxys with three databases containing information about commercial availability: eMolecules, CambridgeSoft ACX and Accelrys ACD (Available Chemicals Directory).
In case of a successful match, icons are displayed beside the compound within the Reaxys interface. Simply click on the icon to access the corresponding service.
Please note: access to ACD and ACX data is provided through Accelrys and CambridgeSoft and requires separate licensing. All the relevant commercial information, including quantity, pricing and vendor information is available within the research workflow.
Security is one of our biggest concerns. Therefore, Reaxys is accessible using HTTPS protocol. This requires port 443 to be open in your institute’s firewall. Since this is a standard setting, it should not be a problem, unless the company prohibits all internet access.
Reaxys supports the following structure editors:
Dotmatics Elemental – default structure editor
Marvin Sketch (ChemAxon)
Symyx Draw (Accelrys)
ChemDraw Pro or higher (CambridgeSoft)
CrossFire Structure Editor (Elsevier)
Please note: if you wish to use structure editors other than Elemental, Marvin Sketch, or GGA Ketcher, a Reaxys plug-in has to be installed (download here). Please refer to Reaxys Help for more information on this topic.
Reaxys was designed to accommodate a number of industry standard structure editors. We will support the CrossFire Structure Editor until it is discontinued, but we will not be further developing or maintaining it. Therefore, we recommend that you switch to one of the many other available editors.
If you wish to use the CrossFire Structure Editor until it is discontinued, you or your information specialist must leave CrossFire Commander installed. If you have specific questions or preferences for structure editor features please don't hesitate to contact us at firstname.lastname@example.org .
Yes. Please Contact Us for more information.
Reaxys has this functionality. To allow the user to change the application settings, save queries and search history and set up alerts, a username and password must be set using the “Register” function. Login queries can then be loaded and saved locally on the workstation and results can be saved.
Technical product info
Download the technical product info for Reaxys and Reaxys Medicinal Chemistry.
Read the technical product info (PDF, 853kb)
Support Log In
Existing Customer? Log into the Reaxys product site and click on Help in the top menu.
Case Studies & Interviews
Amit Tiwari, Head of IP & Scientific Database Operations at Hikal Ltd.F (PDF, 766kb)
Dr. Peter Witte, Research Chemist at BASF (PDF, 855kb)
Ernie Cote, CEO of Chemical Information Services (PDF, 793kb)
Dr. John Parks, director of R&D Fine Chemistry at Albemarle Corporation (PDF, 580kb)
Dr. Jan Haller, a project manager in the Chemical Development Group at Novasep (PDF, 1,92mb)
Dr. Anders Lohse, Vice President of Project Management at NCK (PDF, 797kb)
Dr. Fabio Tucci, co-founder and COO of Epigen Biosciences (PDF, 1.2mb)
Dr. Gary Allred, co-founder, president and CEO of Synthonix (PDF, 670kb)
Dr. Bel Mekonnen is the CEO of the start-up drug discovery organization Hager Biosciences (PDF, 450kb)
Dr. Tommi Meulemans, project manager in Merachem's Organic Synthesis group (PDF, 719kb)
Takahashi Nakai, a medicinal chemist at Ironwood Pharmaceuticals (PDF, 696kb)
Education & Research
Professor Keiji Hirose, Associate Professor at Osaka University (PDF, 600kb)
Professor Forest Robertson of Western Connecticut State University (PDF, 750kb)
Professor Fabrizio Fabris of the University of Venice (PDF, 740kb)
Dr. Maikel Wijtmans of the VU University Amsterdam (PDF, 2mb)